J&J reports 72-week data for Tremfya in plaque psoriasis

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported 72-week data from the Phase III VOYAGE 2 trial of Tremfya guselkumab (CNTO 1959) to treat moderate to severe plaque psoriasis. Tremfya is approved in the U.S., Canada and Europe to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The drug is also under review in Japan.

Of 375 patients who achieved a Psoriasis Area and Severity Index (PASI) 90 response with Tremfya at week 28, 86% who continued receiving Tremfya maintained their PASI 90 response through week 72, while 11.5% who stopped Tremfya and received placebo maintained their PASI 90 response through week 72. Of the 173 patients who stopped Tremfya and lost their PASI 90 response, 87.6% re-achieved a PASI 90 response six months after Tremfya retreatment. Data were presented at the American Academy of Dermatology meeting in San Diego...